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Commonriskfactorsofperiodontitisandcardiovasculardiseasesfuelthedebateoninterrelationshipsbetweenthem.Theaimisto
prove whether statins may inﬂuence periodontal parameters by aﬀecting either of these factors. Out of the 4,290 subjects of SHIP
(Study of Health in Pomerania), we included subjects aged >30 years (219 with statins, 2937 without) and excluded edentulous.
We determined periodontal measures, cholesterol fractions, and inﬂammation markers. Statin use and periodontal risk factors
were assessed. Gingival plaque and periodontal attachment loss were associated with systemic LDL cholesterol (P<0.001) and C-
reactive protein CRP (P = 0.019) revealing interaction with statin use. When adjusted for age, sex, smoking, diabetes, education,
and dental service, statins were identiﬁed as eﬀect modiﬁers abolishing the relationship between attachment loss and LDL and
between gingival plaque and LDL (interactions P<0.001). No statin-related interaction was detected with increase in CRP. The
interaction supports the view of inter-relationships between periodontal and systemic inﬂammatory mediators.
1.Introduction
Periodontitisisaninﬂammatorydiseasecausedbyperiodon-
topathogenic bacteria residing in dental plaque, that is the
bioﬁlm on the tooth surface. It is accompanied by pocket
formationandleadstoattachmentlossandeventuallyresults
in tooth loss. It aﬀects a majority of all adults and is con-
sequently a severe medical challenge.
In recent years, various studies revealed that the local
inﬂammation within the oral cavity is associated with in-
creased levels of markers of systemic diseases. Special atten-
tion was given to the relationships between periodontal dis-
eases and diabetes, cardiovascular disease, and osteoporosis,
among others [1]. Increased blood levels of HbA1c,C R P ,
and cytokines supported the idea that periodontitis may af-
fect or worsen systemic diseases. However, there is much dis-
pute about the direction of cause and eﬀect [2, 3]. A bidirec-
tional relationship may exist between the local periodontitis
and systemic diseases, both of which are inﬂammatory in
nature. Among the factors for which an association with
the severity of periodontitis was reported are the phos-
pholipids, cholesterol, and its subfractions LDL and HDL
(LDL-c, HDL-c). This may be of special interest as it was
hypothesized that there is a close inter-relationship between
cardiovascular diseases and periodontitis. These conditions
share common risk factors such as smoking, diabetes, and
low socioeconomic status.
Thereissubstantialevidencethatperiodontaldiseasesare
associated with elevated systemic cholesterol concentrations.
Presumably, the association between periodontitis and lipid
levels is the consequence of systemic eﬀects of inﬂammatory
stimuli [4]. Concentrations of C-reactive protein (CRP) are
elevated in both conditions.
The HMG CoA reductase inhibitors or statins are the
mosteﬀectiveagentscurrentlyavailabletolowerLDLcholes-
t e r o ll e v e l se ﬀectively. Several clinical trials have demon-
stratedaconsiderablereductionofcardiovascularrisk.Inad-
dition, recent studies suggest that the statins may have other2 ISRN Dentistry
eﬀects beyond the lipid reducing action, especially with re-
spect to inﬂammatory events [5, 6]. Thus, there was some
interest to study statin eﬀects in periodontitis [7, 8]. It was
shown that patients on statin medication exhibited reduced
periodontal injury as compared to subjects without the
drugs[9].Statinmedicationmayhavesomebeneﬁcialeﬀects
when subjects have dental plaque or signs of periodontitis
as gingival bleeding [10]. Thus, the question arises whether
statins may have an inﬂuence on periodontal parameters by
aﬀecting either the inﬂammation or the association between
the disease and the cholesterol concentration or both.
Hitherto, it is unclear if the association is caused by the
lipids or the inﬂammation. Perhaps there is a susceptible
phenotype prone for both, increased lipid levels and inﬂam-
mation. With these associations, it seems reasonable to hy-
pothesize that statins could also have an inﬂuence on the
extent or severity of periodontitis by aﬀecting lipid levels
and/or inﬂammatory stimuli. Thus, it is the aim of this study
to elucidate the statin eﬀects on periodontal disease meas-
ures. This study elucidates such eﬀects in a population-based
health survey study.
2.ParticipantsandMethods
2.1. Study Population. 7,008 subjects were selected by a
cluster sampling method from a population of 210,000
inhabitantsofthenortheasternGermanregionofPomerania
designated as SHIP study (Study of Health in Pomerania).
From 32 communities in the region, a random sample was
drawn from residence registries, stratiﬁed by gender and age.
Finally, 7,008 subjects were sampled, with 292 persons of
each gender in each of twelve ﬁve-year age strata (age range
20–80 years). The net sample (without migrated or deceased
persons) consisted of 6,267 eligible subjects. The ﬁnal SHIP
sample comprised 4,310 participants (response 68.5% of
eligible subjects), of which 4,290 subjects underwent dental
examinations. The design of the SHIP study, recruiting of
participants, and the scope of this population-based cross-
sectional health survey was reported elsewhere [11]. The
participants gave their written informed consent and the
study was approved by the local ethics committee.
2.2. Anamnestic and Periodontal Examinations. Periodontal
status was assessed by specially trained dentists (intraclass
correlation of examiners 0.82–0.91). The examination was
conducted under clinical conditions in a dental chair, partic-
ipants supine, and under optimal lighting, but without saliva
ejector or air drying. Assessment included probing depth,
clinical attachment loss (CAL), plaque, bleeding on probing,
and the number of teeth. Because of the eﬃciency aﬀorded,
the periodontal examination was carried out according to
the half-mouth method on the left or right side in alternate
subjects. All fully erupted teeth were assessed excluding
third molars. A maximum of 14 teeth per subject was
examined. Attachment loss and probing depth were assessed
with a periodontal probe (PCP 11, HuFriedy, Chicago, IL) at
mesiobuccal, distobuccal, midbuccal, and midlingual aspect
on each selected tooth. Attachment loss is represented by the
distance from the cementoenamel junction to the bottom
and probing depth by the distance from the gingival margin
to the bottom of the periodontal pocket. The measurements
were made in whole millimeters.
Visual inspection and probing determined the presence
or absence of marginal plaque. Assessment was performed
at four sites per tooth as mentioned above at three teeth
(midincisor, canine, and ﬁrst molar) in ipsilateral quadrants
(1 and 4 or 2 and 3 alternating from one patient to the next)
using a dental probe. If a test tooth was missing, the distally
adjacent tooth was examined instead. Results were expressed
as percentage of sites with plaque.
Smoking behaviour and socioeconomic status were
assessed with an extensive questionnaire and an interview.
Likewise, the use of medications was assessed and recorded
according to the ATC index [12]. 280 participants were
treated with the following drugs: simvastatin (n = 87),
lovastatin (n = 27), pravastatin (n = 53), ﬂuvastatin (n =
37), atorvastatin (n = 34), and cerivastatin (n = 42).
123 participants were additionally treated with β-blockers
and 74 with calcium antagonists. Fibrates were used by 55
other participants. In order to conﬁrm a regular intake of
the statins, subjects were asked to present evidence of their
use, that is prescriptions or package inserts. Of the 280
subjectstreatedwithstatinsremained219intheﬁnalanalysis
after exclusion of the edentulous from which no periodontal
parameters were available.
2.3. Clinical Chemistry and Statistics. Total cholesterol, LDL-
c, HDL-c, ﬁbrinogen according to the Clauss method, and
HbA1c were determined by standard laboratory methods.
High-sensitivity C-reactive protein (CRP) was determined in
serum by particle-enhanced immunonephelometry (hsCRP
kit, Dade Behring Inc.) with a test sensitivity of 0.2mg/L.
Mann-WhitneyorKruskal-Wallistestswereusedtocompare
the means of two or three groups, respectively. Periodontal
parameters plaque and clinical attachment loss (CAL) were
dividedintotertilsforstratiﬁcation,severecasesdeﬁnedwith
am e a nC A L> 4mm. In logistic regression analyses, mean
CALorplaquewereusedascontinuousvariables.T oimprove
the precision and to reduce correlation between variables,
mean CAL and plaque were centered by subtracting the
overall mean value from each observed value [13]. Clinically
relevant cutoﬀlevelsofLDLcholesterol(LDL-c)withrespect
tocardiovascularriskswereused:<100mg/dL(2.58mmol/L,
optimal), 100 to 160mg/dL (above optimal or borderline),
and >160mg/dL (4.14mmol/L, high). For CRP levels an
arbitrarythresholdof2mg/Lwasset[14].Kruskal-Wallistest
wasusedforcomparisons,logisticregressionformultivariate
analyses. The statistical software STATVIEW 5.0 (SAS, Cary,
NC) was employed.
3. Results
Among the 4,310 participants of the SHIP, we identiﬁed 280
subjects who were treated with statins. Most of them were in
their later life period. Age is an important confounder for all
variables studied. The prevalence of periodontitis increases
with increasing age as it is true for the concentration
of LDL cholesterol. The frequency of statin medicationsISRN Dentistry 3
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Figure 1: (a) Mean LDL-c concentration related to increasing extent of gingival plaque (in tertils) without and with statin use. ANOVA:
statins P<0.001, plaque tertils P = 0.475, interaction P<0.001. (b) Mean LDL-c dependent on severity of attachment loss (mean
CAL tertils) without and with statin use. ANOVA: statins P = 0.003, CAL tertils P = 0.366, interaction statins ∗CAL P = 0.002. Lowest
periodontal tertil—white columns, 2nd tertil—dark columns, 3rd tertil—hatched columns.
increases with age as well. For this study, a subpopulation
was selected with the participants who were aged 30 and
older (in younger participants there were no statin users)
excluding all edentulous subjects. 3,156 participants were
thus included in this analysis. The characteristics of these
subjects are given in Table 1 along with their LDL-c status.
Subjects with high LDL-c levels were older than subjects
within the optimal concentration range. Correspondingly,
periodontal parameters were signiﬁcantly higher as it was
true for markers of systemic inﬂammation (CRP, ﬁbrinogen)
or of glucose homeostasis (HbA1c). Frequency of statin
use was only a third of subjects in the high LDL-c group
as compared with the optimal LDL-c group. We must be
aware that there are presumably four diﬀerent categories
of participants, namely individuals (i) with low LDL-c and
without the drug, (ii) with low LDL-c receiving the drug,
either for prophylaxis or after successful decrease of the lipid,
(iii) not taking statins despite elevated LDL-c levels, and (iv)
persons who take the drug but their LDL-c is still above the
clinically relevant cutoﬀ level.
A ﬁrst crude stratiﬁcation according to the extent of
gingival plaque (Figure 1(a)) or the severity of attachment
loss (Figure 1(b)) resulted in the plots showing the level of
LDL-c with and without statins with increasing periodon-
titis. In each case, the diﬀerences associated with statin use
suggest the presence of interaction. The statins themselves or
the medical indications for their use aﬀect the relationship
betweenthedentalparametersandtheirsystemiccorrelatein
such a way that the increased LDL-c associated with higher
plaque or attachment loss was attenuated. Similarly, CRP
levels were increased in subjects with periodontitis, an in-
crease which was not observed in subjects under statin
medication (Figure 2).
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Figure 2: Severe periodontitis (mean CAL > 4mm, dark columns;
white columns CAL ≤ 4mm) is associated with an increase in CRP,
which is attenuated by statins. ANOVA: statins P = 0.992, CAL P =
0.019, interaction P = 0.024.
We performed multiple regression analyses with the bor-
derline and the high LDL-c levels as dependent variables,
adjusting for potential confounding or inﬂuential factors.
Periodontal parameters were associated with increased risk
of high LDL-c. Statin use showed lower risk exhibiting sig-
niﬁcant interaction with the periodontitis factors. A com-
parison of the odds ratios between medium and high LDL
as dependent variables revealed a reasoned gradation for the
periodontitisparametersandtheinteractionfactorswithsta-
tins (optimal < 100mg/dL as reference). Statin interaction
with plaque (Table 2) resulted in odds ratio OR = 0.96 and
0.77 (P<0.001) for LDL-c 100–160mg/dL and >160mg/dL,
respectively. Interaction ﬁgures for mean attachment loss in4 ISRN Dentistry
Table 1: Characteristics of the subjects and their distribution ac-
cording to their serum LDL cholesterol state.
LDL concentration range, mg/dL
Subjects with <100 ≥100–<160 ≥160 P
Number of
subjects 545 1679 942 —
Age, years 47.9 ±13.35 1 .7 ±13.45 4 .5 ±12.1 <0.001
Dentist seen >1
year before∗ 9.4 10.4 11.8 0.309
Education <10th
grade∗ 31.0 37.9 46.5 <0.001
Smoking, pack
years 8.4 ± 13.78 .7 ±14.29 .9 ±15.1 0.882
Alcohol,
g/weekend
47 ±65 45 ±59 41 ±53 0.042
Statin
medication∗ 11.6 7.1 3.9 <0.001
Metabolic
characteristics
LDL, mmol/L 2.1 ±0.43 .4 ±0.45 .0 ±0.8 <0.001
HDL, mmol/L 1.6 ±0.61 .4 ±0.41 .4 ±0.4 <0.001
hsCRP, mg/L 2.9 ±5.12 .8 ±4.73 .0 ±6.8 0.003
Fibrinogen, g/L 2.9 ±0.63 .0 ±0.73 .2 ±0.7 <0.001
HbA1c,% 5 . 3± 0.9 5.4 ± 0.9 5.6 ± 0.9 <0.001
Periodontal
characteristics
No. of teeth† 19.9 ±7.21 9 .0 ±7.71 7 .6 ±8.0 <0.001
Attachment loss,
mean mm 2.5 ±1.82 .9 ±1.93 .3 ±1.9 <0.001
Probing depth,
mean mm 2.5 ±0.72 .6 ±0.82 .7 ±0.8 <0.001
Attachment loss,
% ≥4mm ‡ 10 (40) 21 (52) 31 (60) <0.001
Plaque, %of
sites‡ 50 (54) 54 (51) 60 (54) <0.001
B O P ,%o fs i t e s ‡ 29 (38) 35 (42) 38 (44) <0.001
∗Percent of subjects, †excluding the 3rd molars and zero ﬁgures, ‡median
(interquartile range).
mm (Table 3)w e r eO R= 0.98 (P = 0.046) and 0.96 (P<
0.001), respectively.
If no interaction exists, then the increased risk of having
high LDL-c levels due to periodontitis would be the same
regardless of the individual’s drug treatment. Since statin
use and gingival plaque or attachment loss interact, the risk
of high LDL-c from an increase in periodontitis ﬁgures is
associated with the drug. Probably, statins reduce LDL-c so
eﬀectively that it remains low irrespective of whether there
is plaque-related challenge or not. Likewise, since statin use
and attachment loss interact in this analysis, the risk of high
LDL-c concentrations from an increase in attachment loss
may be modulated by the drug. In this sense statins act as
eﬀect modiﬁers.
Table 2: Logistic regression: dental plaque (extent in 10% incre-
ments) and the risk of belonging to the LDL concentration range
100–160mg/dL or >160mg/dL with reference LDL < 100mg/dL.
Dependent
variable
LDL 100–<160mg/dL LDL ≥ 160mg/dL
OR (95% CI) P OR (95% CI) P
Plaque, crude 1.03
(1.00–1.06) 0.099 1.08
(1.04–1.12) <0.001
Model 1∗
Plaque 1.00
(1.00–1.04) 0.998 1.03
(0.99–1.07) 0.130
Model 2∗
Plaque 1.00
(0.97–1.04) 0.990 1.04
(1.00–1.08) 0.081
Statins 0.37
(0.26–0.54) <0.001 0.14
(0.09–0.23) <0.001
Plaque ×
statin use
0.96
(0.86–1.08) 0.512 0.77
(0.66–0.89) <0.001
∗Model 1: adjusted for age (continuous), sex (male 0, female 1), HbA1c
(continuous), education (10th grade or higher), smoking (pack years),
alcohol consumption (g/weekend), and last dental visit (within the last year
0, longer than one year 1).
∗Model 2: as model 1 with the additional variables shown.
Table 3: Logistic regression: mean clinical attachment loss (CAL)
and the risk of belonging to the LDL concentration range 100–
160mg/dL or >160mg/dL with reference LDL < 100mg/dL.
Dependent
variable
LDL 100–<160mg/dL LDL ≥ 160mg/Dl
OR (95% CI) P OR (95% CI) P
CAL, mm, crude 1.17
(1.10–1.25) <0.001 1.30
(1.21–1.39) <0.001
Model 1∗
CAL mean, mm 1.08
(1.00–1.16) 0.064 1.11
(1.02–1.21) 0.013
Model 2∗
CAL mean, mm 1.11
(1.02–1.20) 0.020 1.21
(1.10–1.33) <0.001
Statins 0.36
(0.24–0.53) <0.001 0.14
(0.08–0.22) <0.001
CAL × statin use 0.98
(0.97–1.00) 0.046 0.96
(0.94–0.98) <0.001
∗Model 1: adjusted for age (continuous), sex (male 0, female 1), HbA1c
(continuous), education (10th grade or higher), smoking (pack years), al-
cohol consumption (g/weekend), and last dental visit (within the last year 0,
longer than one year 1).
∗Model 2: as model 1 with the additional variables shown.
Similarly, we performed logistic regression analyses with
a CRP cutoﬀ of 2mg/L as dependent variable and identical
independent variables as in Table 2. Odds ratios of belonging
to the high CRP group OR = 1.06 (1.04–1.09, P<0.001)
and OR = 1.11 (1.05–1.17, P<0.001) were calculated for
plaque (10% increments) and mean attachment loss in mm,
respectively. The probability of belonging to the high CRP
group was insigniﬁcantly lower with statins (OR = 0.79, C.I.ISRN Dentistry 5
0.58–1.07, P = 0.123). There was no interaction with these
periodontal measures.
In order to address the question if the subjects treated
with statins were diﬀerent from those without, we compared
diﬀerent risk factors among these groups. Subjects treated
with statins or not were basically diﬀerent from each other,
especially those with elevated systemic inﬂammation marker
CRP (data not shown). The subjects without statins had
lower socioeconomic status as indicated by education and
income. Signs of poor oral hygiene were indicated by high
extent of plaque and bleeding on probing. Thus, diﬀerent
reasonsforprescribingstatinsmaycontributetotherelation-
ships shown.
4. Discussion
In this study we reported that the statistical association of
gingivitis and periodontitis with risk factors for cardiovas-
cular sequelae was modulated by statins. After stratiﬁcation
according to periodontal measures, an eﬀect modiﬁcation by
statins aﬀecting the LDL-c level was observed.
Gingival plaque is a bioﬁlm which consists of numerous
diﬀerent bacterial species nourished from bleeding gingiva,
saliva, and crevicular ﬂuid. In general, it is believed that this
bioﬁlm induces an inﬂammatory response to counteract the
bacterial challenge. On the other hand, gingival plaque accu-
mulates preferentially on those sites which are deteriorated
by inﬂammation [15]. Various reports have demonstrated
an eﬀect of dental plaque on the systemic inﬂammatory
response [16] and on the level of circulating lipids including
cholesterol [17]. This mutual inﬂuence of inﬂammation and
bacterial bioﬁlm has its mirror image in the relation between
periodontalinﬂammationandsystemicreactionsasreﬂected
by increases in phospholipids, cytokines, and markers of
inﬂammation, namely, ﬁbrinogen, CRP, and so forth, which
maypotentially mediatetheconnectionbetweenperiodontal
and cardiovascular diseases [18].
Intervention studies reporting eﬀects of periodontal
treatment on systemic parameters such as cholesterol and
CRP give evidence of a causal direction oral inﬂammation >
systemic eﬀect. Chronic inﬂammation induced by plaque
leads to attachment loss and ﬁnally to tooth loss. As sug-
gested by the associations shown, there are diﬀerent inter-
relationships between the local inﬂammation and the sys-
temic responses. Periodontitis and cardiovascular diseases
share common risk factors, and several reports showed that
periodontitis is accompanied by systemic inﬂammation and
increasing concentrations of circulating phospholipids [18,
19]a sw e l la sm a r k e r so fi n ﬂ a m m a t i o n[ 20]. Plaque removal
by local periodontal therapy reduces total and LDL-c as well
as circulating CRP [21]. The association shown in our study
regarding the statin eﬀects may lead to speculations that
also an opposite relationship could exist. Notwithstanding,
a quite simple explanation for the eﬀects shown is that the
statinsaﬀectLDL-candCRPinawaypreventinganyincrease
from periodontal stimuli.
With regard to odontogenic septicemia it was speculated
whether statins could play a role in the interaction between
periodontitis and cardiovascular diseases [22]. However, an-
timicrobial eﬀects of statins on dental bioﬁlm bacteria as
claimed by some authors [23] are less probable as statins
are much less potent inhibitors of bacterial HMG-CoA
reductases than of the human enzyme variant [24]. Elevated
levels of CRP are associated with infection by subgingival
organisms related to periodontal disease, including Porphy-
romonas gingivalis and Prevotella intermedia [25]. It has
been shown that high glucose concentrations enhance LPS-
induced expression of inﬂammatory cytokines and simvas-
tatin largely blocks this enhanced expression [26].
In vitro experiments in cell lines modelling gingival
tissue revealed that simvastatin reduces the interleukin-1α-
inducedproductionofinﬂammatorycytokinesIL-6andIL-8
[23]. This eﬀect resulted from speciﬁc inhibition of HMG-
CoA reductase. Thus, the association shown here reﬂect
probably diminished LDL-c levels in the systemic circulation
associated with reduced inﬂammation in the gingiva and
concomitantly reduced plaque. On the other hand, complete
extraction of all teeth (and thus, removal of all plaque)
reduces the circulating markers of inﬂammation, namely,
CRP, ﬁbrinogen, and white blood cells [27]. A signiﬁcantly
reduced number of pathological periodontal pockets in pa-
tients taking simvastatin or atorvastatin has been reported
[9]. Moreover, treatment of periodontitis is followed by a de-
crease in systemic markers of inﬂammation including IL-6
[28,29],aneﬀectmimickedinvitrobysimvastatininepithe-
lial cells [22]. Statins also reduce the production of IL-1β and
TNFα, inﬂammatory cytokines which are known to play a
pivotal role in periodontitis [30]. While the LDL-c reduction
by statins has unequivocally beneﬁcial consequences, the
eﬀects induced by lowering the inﬂammatory markers are
less clear [31]. Most of the widely discussed “pleiotropic”
eﬀects of statins correlate with the extent of lipid lowering,
for example, the reduction of CRP [29].
The study has some limitations. There was no informa-
tion available on how long statins were already used, al-
though these drugs are supposed to be taken for chronic use.
Diﬀerent types of statins were lumped together. Notwith-
standing, all statins have shown similar eﬃcacy in reducing
CRP levels [32]. Due to the cross-sectional setting, a caus-
ative sequence cannot be deduced from the interactions
of cholesterol concentrations, CRP levels, periodontal mea-
sures, and statin treatment. The sequence of eﬀects could not
be elucidated.
In this study, we described the statins as eﬀect modiﬁers
intherelationshipbetweenperiodontitisanditsinﬂammato-
ry counterparts in the systemic circulation. Statins could
attenuatetheinﬂammation-relatedsystemiceﬀects.Control-
led clinical trials using systemically or locally administered
statins have shown signiﬁcant improvements of periodontal
sequelae [33, 34].
5. Conclusion
Gingival plaque and periodontal attachment loss were asso-
ciated with elevated levels of systemic LDL/HDL cholesterol
and C-reactive protein. In participants treated by statins, this
periodontitis-related increase was abolished. If conﬁrmed6 ISRN Dentistry
by clinical studies, the lipid-lowering statins would be pro-
mising drugs to prevent periodontitis-related increases in
cardiovascular risk markers.
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